MedTrace Logo

Lifetech CeraFlex™ ASD Closure System Post-Market Clinical Follow-Up

NCT05887700 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 145

Last updated 2025-01-08

No results posted yet for this study

Summary

The objective of this post-market registry is to assess the clinical use of the Lifetech CeraFlex™ Closure System in a real-world and on-label fashion.

Conditions

  • Atrial Septal Defect

Interventions

DEVICE

CeraFlex™ Atrial Septal Defect (ASD) Closure System

The CeraFlex™ ASD Occluder have two types of occluders, CeraFlex™ ASD Occluder and CeraFlex™ Multi-fenestrated (Cribriform) ASD Occluder. The CeraFlex™ ASD Occluder is percutaneous, transcatheter closure devices for the non-surgical closure of atrial septal defects.

Sponsors & Collaborators

  • Lifetech Scientific (Shenzhen) Co., Ltd.

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-09
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Brazil
  • Greece
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05887700 on ClinicalTrials.gov